Q-omics provides the consensus-scored LRRC29 profile across patient tissues and cancer cell-line models. LRRC29 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LRRC29 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LRRC29 RNA expression shows 15,710 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where LRRC29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC29 survival associations across molecular data types. LRRC29 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC29 RNA expression–survival associations across cancer types. High LRRC29 expression shows unfavorable associations in COAD, but favorable associations in UCEC, MESO, SARC, PAAD and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for LRRC29 RNA expression.
This table summarizes LRRC29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC29 shows lower tumor expression in UCEC and BRCA and higher tumor expression in KIRC, COAD, THCA and LIHC. The KIRC box plot shows higher LRRC29 RNA expression in tumor versus normal tissue (log2 FC = +0.722, t-test p < 0.001).
This table shows molecular features associated with LRRC29 in patient tissues and cancer cell lines. In patient samples, LRRC29 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
